Wednesday - May 14, 2025
ALPHARETTA, Ga., March 15, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president, chief financial officer and chief transformation officer, will present and participate in an analyst-led fireside chat at the 2023 virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wed., March 22 at approximately 9:45 a.m., ET.
A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.
About Avanos Medical
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. For more information, visit Avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.
Last Trade: | US$12.15 |
Daily Change: | -0.56 -4.41 |
Daily Volume: | 588,245 |
Market Cap: | US$558.410M |
May 06, 2025 February 26, 2025 November 12, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load